ACS chemical neuroscience molecule spotlight on Latuda (lurasidone; SM-13,496)

ACS Chemical Neuroscience

Volumn 2, Issue 2, 2011, Pages 58-59

  Hopkins, Corey R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATUDA; LURASIDONE; UNCLASSIFIED DRUG;

AKATHISIA; DROWSINESS; DRUG ACTIVITY; DRUG APPROVAL; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MOTOR DYSFUNCTION; NAUSEA; NOTE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DOPAMINE ANTAGONISTS; HUMANS; ISOINDOLES; NEUROSCIENCES; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SOCIETIES, SCIENTIFIC; THIAZOLES;

EID: 79951818854     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn1001123     Document Type: Note

References (6)

1. Wu, E. Q., Birnbaum, H. G., Shi, L., Ball, D. E., Kessler, R. C., Moulis, M., and Aggarwal, J. (2005) The economic burden of schizophrenia in the United States in 2002 J. Clin. Psychiatry 66, 1122-1129
2. Ishiyama, T., Tokuda, K., Ishibashi, T., Ito, A., Toma, S., and Ohno, Y. (2007) Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test Eur. J. Pharmacol. 572, 160-170
3. 1A receptor activity J. Pharmacol. Exp. Ther. 334, 171-181
4. Nakamura, M., Ogasa, M., Guarino, J., Phillips, D., Severs, J., Cucchiaro, J., and Loebel, A. (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial J. Clin. Psychiatry 70, 829-836
5. Results presented at the American College of Neuropsychopharmacology (ACNP) 49th Annual Meeting, Miami, FL, December 8, 2010.
6. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm.